SXTPMEDIUM SIGNALFINANCIAL10-K

SXTP executed a reverse stock split and showed improving operational efficiency with 65% revenue growth and significant cost reductions, though cash burn remains concerning.

The reverse stock split (approved October 2025) nearly doubled the outstanding share count from 1.47M to 2.64M shares, indicating potential dilution concerns or compliance issues. While the company improved operational metrics with strong revenue growth and reduced R&D/interest expenses, the worsening operating cash flow burn suggests ongoing liquidity challenges.

Comparing 2026-03-30 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

SXTP demonstrated mixed financial performance with revenue growing 65.5% to $1.0M and operating losses improving 20% as R&D expenses dropped 57.8% and interest expenses fell 42.7%. However, operating cash flow deteriorated 21% to -$6.8M while stockholders' equity declined 14.2% to $3.5M, indicating the company is burning through capital faster despite operational improvements. The inventory increase of 48% suggests either growing business activity or potential working capital management issues.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+65.5%
$608K$1.0M

Strong top-line growth of 65.5% — accelerating demand or successful expansion into new markets.

R&D Expense
P&L
-57.8%
$5.0M$2.1M

R&D spending cut 57.8% — could signal cost discipline or concerning reduction in innovation investment.

Inventory
Balance Sheet
+48.4%
$443K$657K

Inventory surged 48.4% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
-42.7%
$4.0M$2.3M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+34.8%
$104K$140K

Capital expenditure jumped 34.8% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-21.3%
-$5.6M-$6.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Operating Income
P&L
+20.1%
-$9.7M-$7.8M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Stockholders Equity
Balance Sheet
-14.2%
$4.0M$3.5M

Equity decreased 14.2% — buybacks or losses reducing book value, monitor solvency ratios.

Current Liabilities
Balance Sheet
+11.2%
$1.7M$1.8M

Current liabilities rose 11.2% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+10.1%
$1.8M$2.0M

Liabilities increased 10.1% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-27
ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12 b- 2 of the Exchange Act.
7262 (b)) by the registered public accounting firm that prepared or issued its audit report.
As of March 30, 2026 the Registrant had 2,636,788 shares of common stock, par value $ 0.0001 per share, issued and outstanding.
Currently, 60P s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
We own 97% equity in 60P Australia Pty Ltd, a Sydney, Australia-based subsidiary ( 60P Australia ).
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D .
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
7262(b)) by the registered public accounting firm that prepared or issued its audit report.
As of March 27, 2025 the Registrant had 1,472,891 shares of common stock, par value $0.0001 per share, issued and outstanding.
Currently, 60P s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →